Introduction

By definition, ‘suspended animation’ is a hypometabolic state characterized by the “the slowing of life processes by external means without termination” [1]. Various mammalian species are capable of nearly completely shutting down their vital functions in order to survive otherwise lethal environmental conditions, such as prolonged impairment of O$_2$ supply and/or extreme temperatures. First described and studied in patients as “hibernation artificielle” induced by the so-called “cocktail lytique” during the Indochina war in the early 1950 s, for obvious reasons the concept of inducing such a hypometabolic condition has attracted special interest in intensive care and emergency medicine. Originally, organ-protection, in particular for the central nervous system (CNS), was demonstrated when suspended animation was induced by rapidly cooling experimental animals to core body temperatures of about 10–15 °C using ice-cold infusions and/or cardiopulmonary bypass (CPB). Given the potential undesired adverse effects of hypothermia per se, e. g., metabolic acidosis, coagulopathy, prolonged inflammation, and impaired host defense, any pharmacological measure allowing for a therapeutic on-demand induction of suspended animation would be of particular interest. Moreover, more recently, it was suggested that the reduced visceral organ function present in critically ill patients and/or after overwhelming hyperinflammation could be referred to as an adaptive mechanism to maintain ATP-homeostasis due to reduced energy expenditure rather than to irreversible organ failure [2]. A landmark paper by Blackstone et al. demonstrated that mice inhaling hydrogen sulfide (H$_2$S) reversibly decreased their energy expenditure, which was associated with a fall in core temperature [3]. In the meantime, numerous pre-clinical studies have been published on the possible organ-protective effects of H$_2$S, the available data being equivocal depending on the model used and the type of shock investigated. In this context in particular, the impact of H$_2$S effects on energy metabolism remains a matter of debate. Therefore, the present chapter reviews the available data on H$_2$S-induced on-demand hypometabolism, and its relation (directly as well as via a possible consecutive drop in body temperature) to organ-protective properties of H$_2$S.

Rodent models

In their above-mentioned murine study, Blackstone et al. demonstrated, in awake, spontaneously breathing animals, that exposure to incremental, sub-toxic gaseous H$_2$S concentrations (20–80 ppm) dose-dependently decreased energy expenditure within a few minutes as assessed by calorimetric measurement of whole-body O$_2$ uptake and CO$_2$ production. This fall in metabolic activity was associated with bradypnea and consecutive hypothermia, with core temperature falling to levels close to ambient values [3]. After washout of H$_2$S, all these metabolic and cardiopulmonary effects were completely reversible, and animals showed no apparent sequelae. Subsequently, Volpato et al. reported that the reduced metabolic activity went along with bradycardia and, consequently, reduced cardiac output, whereas blood pressure and stroke volume remained unaffected [4]. Maintenance normothermia by external warming attenuated the metabolic depressor effect, but did not completely blunt the cardiovascular response [4]. Various other rodent models confirmed these observations: Inhaling gaseous H$_2$S [5]–[12] and infusing the soluble sulfide salts, NaSH or Na$_2$S [6], [13], [14], also induced a reversible reduction in energy expenditure with a
subsequent fall in core temperature. Under stress conditions resulting from injurious mechanical ventilation [8], [13], ischemia/reperfusion [7], [9], [12], endotoxin challenge [11], or bacterial sepsis [14], this effect coincided with attenuation of lung [8], [12]–[14], liver [9], kidney [7] and heart [12] injury. Most importantly, survival was improved after otherwise lethal stress states, e. g., hemorrhagic shock [6] and exposure to hypoxic hypoxia (fraction of inspired O\textsubscript{2} [FiO\textsubscript{2}] 5 %) [5]. In addition to anti-oxidant, anti-inflammatory, and anti-apoptotic properties, H\textsubscript{2}S was associated with better maintenance of mitochondrial integrity and function [7], [15], [16]: Treatment with either gaseous H\textsubscript{2}S treatment or injection of Na\textsubscript{2}S prevented mitochondrial swelling, loss of crypts [7], [15], and, at least under hypothermic conditions, outer mitochondrial membrane rupture as documented by the lack of responsiveness of the mitochondrial respiratory chain to stimulation with exogenous cytochrome c [16].

It should be noted that most of the above-mentioned murine data originate from experiments in awake, spontaneously breathing animals. Consequently, the role of anesthesia for a putative H\textsubscript{2}S-induced suspended animation remains unclear. Currently, scarce literature is available comparing the effects of anesthesia and H\textsubscript{2}S per se. In spontaneously breathing mice, Li et al. demonstrated that H\textsubscript{2}S (80 and 250 ppm) produced the same metabolic depression as 0.3 and 0.9 % of isoflurane, respectively, however, without any anesthesia-related muscle atonia. Strikingly, when combining these two interventions, H\textsubscript{2}S even antagonized the isoflurane-induced metabolic depression [17]. Finally, in mechanically ventilated mice under continuous intravenous (i.v.) anesthesia, the metabolic depressor effect of H\textsubscript{2}S was completely blunted when normothermia was maintained [16].

**Large animal species and humans**

Any metabolic depressant property of H\textsubscript{2}S seems to be dependent on the animal size: In rats the H\textsubscript{2}S-induced decrease in O\textsubscript{2} uptake was several-fold lower than in mice [18]. In larger species (swine, sheep), various authors failed to confirm any H\textsubscript{2}S-related reduction in metabolic activity at all, regardless of whether inhalation of gaseous H\textsubscript{2}S or injection of sulfide salts were studied [19]–[22]. Moreover, in sheep, Derwall et al. [23] demonstrated that during administration of gaseous H\textsubscript{2}S via an extracorporeal, veno-arterial membrane oxygenator to avoid any airway mucosa damage related to the gas inhalation [24], [25], whole body O\textsubscript{2} uptake, CO\textsubscript{2} production, and cardiac output remained within the physiological range. At the highest doses administered (300 ppm), H\textsubscript{2}S did not affect calorimetric energy expenditure either, but caused pulmonary vasoconstriction associated with arterial hypotension and metabolic acidosis [23]. Finally, in human volunteers, inhalation of 10 ppm H\textsubscript{2}S during exercise decreased O\textsubscript{2} uptake, and this effect was referred to a toxic reduction in maximal aerobic capacity rather than to a regulatory effect on mitochondrial respiration, as evidenced by a tendency for muscle lactate to increase and citrate synthase activity to decrease [26]. Consequently, it was questioned whether any therapeutic potential of the H\textsubscript{2}S-induced "suspended animation"-like hypometabolism observed in mice and rats could be transferred to the clinical setting [27], [28]. On the other hand, when external measures to prevent hypothermia were withheld, Na\textsubscript{2}S-related organ-protection after kidney ischemia/reperfusion-injury [29] or hemorrhage and resuscitation [30] coincided with a progressive decrease in core temperature (Figure 1). Moreover, in the latter experiments, immediate post-mortem liver tissue mitochondrial activity showed a tendency towards both reduced oxidative phosphorylation and maximal O\textsubscript{2} uptake in the uncoupled state, and, in particular, a significantly decreased "leak respiration"; i. e., the respiratory activity necessary to compensate for the proton leakage, slipping, and cation-exchange along the inner mitochondrial membrane (Figure 2). In other words, H\textsubscript{2}S supplementation under these conditions provided protective reduction rather than toxic inhibition of cellular respiration.

How can these diverging findings be reconciled? Under stress conditions, e. g., in response to hypoxia or circulatory shock, small rodents can reduce their energy expenditure as a result of decreased 'non-shivering thermogenesis' [31], due to modulation of the uncoupling protein-1, mostly in the brown adipose tissue [32]. In these species, non-shivering thermogenesis represents a large proportion of total O\textsubscript{2} uptake, which can be rapidly decreased without affecting ATP formation [31]. This response is independent of any pharmacological intervention, and represents a unique protective adaptation present in numerous mammals [31] and even in humans, e. g., in neonates and during cold acclimatization [32]. However, due to the high area/volume ratio and, consequently, the higher heat dissipation, it is inversely related to body size [31], i. e., to the ratio of O\textsubscript{2} consumption and body weight. Two phenomena support this latter notion: i) No matter the species, newborns present with more pronounced hypoxia-induced hypometabolism than do adults [31]; ii) when the ratio of O\textsubscript{2} consumption and body weight per se is low (e. g., in adults of larger species), normoxic O\textsubscript{2} uptake (e. g., during exercise [31]) may be associated with hypoxia-induced hypometabolism. Hence, if possible at all, achieving a suspended animation-like status in larger animals and humans will be more difficult and require much more time because of the small surface area/mass ratio: In fact, in anesthetized and mechanically ventilated...
swine, after four hours of Na₂S infusion whole body O₂ uptake and CO₂ production started to decrease, subsequently resulting in a moderate decrease in core temperature at ten hours of drug infusion [23] (Fig. 1).

No matter the current debate on the feasibility of pharmacological induction of whole body suspended animation in larger animals, inducing hypometabolism to hibernate isolated organs and, thereby, prolong their tolerance against tissue ischemia or hypoxia remains an attractive option, in particular for organ transplantation. Numerous studies in rodents have demonstrated that H₂S administration improved kidney, liver heart, and lung function and attenuated histological damage after orthotopic organ transplant. This beneficial effect of H₂S administration (NaSH 0.5 mmol/l over 10 minutes before and immediately after initiation of reperfusion) was confirmed in isolated porcine kidneys ex vivo undergoing normothermic reperfusion with autologous blood after 25 minutes of warm ischemia and subsequently 18 hours of storage at 4 °C [33].

Figure 1. Time course of body core temperature in swine undergoing (a) 90 minutes intra-aortic balloon occlusion-induced kidney ischemia/reperfusion-injury (data are adapted from [29]: Dark blue squares, vehicle n = 10; blue circles, Na₂S n = 9; all data are mean ± SD, § designates p < 0.05 between groups); (b) hemorrhage and resuscitation (data are adapted from [30]: black squares, vehicle n = 14; dark blue squares, Na₂S started two hours before hemorrhage, n = 10; light blue squares, Na₂S started simultaneously with hemorrhage, n = 11; blue triangles, Na₂S started immediately after hemorrhage, n = 10; all data are mean ± SD, § designates p < 0.05 ‘simultaneous’ treatment vs. vehicle). Note that in both experimental series at least four hours of drug infusion were necessary to achieve a significant decrease in body temperature.
hypothermia observed simultaneously with H₂S-induced organ-protection may also be due to attenuation of systemic inflammation rather than to reduced energy expenditure per se. In other words, such findings raise a ‘chicken and egg’ problem, which can be attributed to the so-called Q10 effect, i. e., the two to three fold reduction in all chemical reactions and thus metabolism associated with a 10 °C-reduction of body temperature [31]: As an example, during otherwise lethal porcine hemorrhage, therapeutic hypothermia was associated with reduced concentrations of pro-inflammatory cytokines [43]. The potential of H₂S acting as a metabolic depressant in larger species independent of any anti-inflammatory and antioxidative property still remains unsettled: In the above-mentioned swine study showing an H₂S-induced drop in O₂ uptake and CO₂ production as well as a consecutive moderate fall in core temperature, animals underwent a short period of aortic occlusion, which did not cause any increase in the blood levels of pro-inflammatory cytokines or markers of oxidative and nitrosative stress [23].

Irrespective of the question as to whether or not there is cause-effect relationship between H₂S-related organ protection and coinciding hypometabolism and/or hypothermia, hypothermia does assume importance for H₂S-induced effects on substrate utilization and mitochondrial function. It is well-established that H₂S toxicity is due to inhibition of mitochondrial respiration resulting from blockade of the complex IV of the respiratory chain, i. e., cytochrome c oxidase [44]. When compared to normothermia, hypothermia (27 °C) increased the Na₂S concentrations necessary to induce inhibition of mitochondrial respiratory activity (from < 1 μM to 2–4 μM), and nearly doubled the Na₂S concentrations required for a 50 % reduction in mitochondrial respiratory activity [16], [45]. Hypothermia may also influence the effect of H₂S on substrate utilization and, thereby, may even improve the yield of the mitochondrial respiration: In anesthetized and ventilated mice, during normothermia, inhaling 100 ppm H₂S did not affect endogenous glucose production (as calculated from the rate of appearance of 1,2,3,4,5,6-¹³C₆-glucose during continuous i.v. isotope infusion), whole body CO₂ production, or direct, aerobic glucose oxidation rate (as derived from VCO₂ and the expiratory ¹³CO₂/¹²CO₂ ratio) (Fig. 3). However, under hypothermic (core temperature 27 °C) conditions, the rate of direct, aerobic glucose oxidation increased, suggesting a shift toward preferential carbohydrate utilization [16] (Fig. 3). Such a switch in fuel utilization is associated with an improved yield of oxidative phosphorylation: The ATP synthesis/O₂ consumption ratio is higher for glycolysis than for β-oxidation, because nicotinamide adenine dinucleotide (NADH) as an electron donor provides three coupling

**Hypothermia**

Equivocal data are available whether hypothermia, caused by a possible H₂S-related fall in energy expenditure and/or due to external cooling measures, assumes importance for organ protection achieved during H₂S administration. Inhaling H₂S prior to myocardial ischemia at concentrations that had no metabolic depressant effect (10 ppm) attenuated organ damage, but to a lesser degree than concentrations that reduced energy expenditure (100 ppm) [12], suggesting that hypometabolism may indeed enhance the organ-protective properties of H₂S. Of note, in that study as well as in others demonstrating H₂S-related organ production coinciding with reduced metabolic activity, hypothermia was prevented [5], [7], [9], [14],[15] in order to elucidate the impact of a simultaneous drop in core temperature. Moreover, organ protection and improved survival were also shown to be in part [12], [13], [15], [34], [35] or even completely [8], [11], [36], [37] independent of any H₂S-induced metabolic depression at all. Finally, data obtained in large animal (swine or sheep) models of shock resulting from ischemia/reperfusion [29], [38]–[42], hemorrhage and resuscitation [30], or burn injury [36] also suggested that the beneficial effects of infusing Na₂S were at least in part independent of metabolic depression and/or a fall in core temperature. Hence, any moderate
sites rather than just two from FADH$_2$ [46]. During cecal ligation and puncture-induced septic shock, the metabolic effects of inhaled H$_2$S partially disappeared: Inhaled H$_2$S affected neither the sepsis-induced metabolic acidosis [34] nor glucose utilization (Figure 3), nor the responsiveness to stimulation with exogenous cytochrome c oxidase. Nevertheless, H$_2$S did normalize the sepsis-related increase in “leak respiration” – which was less pronounced during hypothermia – thus allowing for better maintenance of mitochondrial function (Figure 4).

It is unclear whether the lack of effect of H$_2$S on the mitochondrial respiratory chain was due to the septic challenge per se and/or to the ongoing treatment: During sepsis, all mice needed continuous i.v. norepinephrine to achieve target hemodynamics characterized by a normotensive and hyperdynamic circulation. In turn, norepinephrine incubation was associated with impairment of tissue mitochondrial respiration.

**Timing and dose**

No matter the importance of hypometabolism for the organ-protective properties of H$_2$S administration per se,
injection of NaSH or Na₂S can prevent organ damage regardless of whether the Na₂S infusion was started two hours before (pre-treatment: survival 100 %) or simultaneously with (survival 91 %) the initiation of hemorrhage, or at the start of re-transfusion of shed blood (post-treatment: survival 90 %) [30]. However, a significant decrease in core temperature (Fig. 1b) and organ protection were only present in the group of animals treated simultaneously with the initiation of hemorrhage. Apparently, both the cumulative H₂S dose as well as the rate of its generation assume importance for the effects on metabolism and organ protection, in particular under low flow conditions and/or circulatory shock: In swine undergoing cardiac arrest, primed-continuous Na₂S (0.3 mg/kg followed by 0.3 mg/kg/h over two hours) injected one minute after the start of cardiopulmonary resuscitation (CPR) reduced blood pressure and cardiac output during early resuscitation [21]. Increasing the Na₂S dose (1.0 mg/kg followed by 1.0 mg/kg/h) was associated with impaired neurological recovery. Even injection of comparable total amounts may have markedly different effects due to the different rate of H₂S generation: *In vitro* slow H₂S release from the H₃ donor GYY4137 exerted anti-inflammatory and -apototic effects, whereas short-term, high peak free sulfide levels resulting from incubation with NaSH induced the opposite response [48]. *In vivo*, this concept was confirmed in swine undergoing myocardial ischemia/ reperfusion injury: A primed-continuous Na₂S infusion was superior to bolus injection [39].

**Conclusions**

The concept of “buying time in suspended animation” [49] has been discussed in the literature for more than a century. Originally induced by rapid external body cooling, any pharmacological measure allowing for a therapeutic, on demand induction of ‘suspended animation’ is of particular interest because of the undesired side effects of hypothermia per se. Therefore, the landmark paper demonstrating that inhaling H₂S could induce a reversible, suspended animation-like hypometabolism [3], produced much excitement among researchers in the field of shock and critical illness. Numerous pre-clinical studies are currently available on H₂S-related organ protection, but the effects on energy metabolism remain a matter of debate. In this context, the well-established toxic blockade of cytochrome c oxidase by H₂S may assume particular importance. Most studies so far suggest that the beneficial effects of H₂S are at least in part independent of an H₂S-induced metabolic depression and, in particular, any decrease in core temperature. However, other data suggest that H₂S-related hypometabolism may enhance the organ-protective properties. The mechanism behind H₂S-induced hypometabolism is still not fully understood, and, moreover, the feasibility of H₂S-induced suspended animation in larger animals has been questioned. Clearly, if possible at all, achieving a suspended animation-like status in larger animals and humans will be more difficult and require much more time because of the small surface area/mass ratio. Again the available data are equivocal, suggesting that at least hibernating isolated organs remains an option. Even in larger species, data on the effects of H₂S on mitochondrial function and morphology suggest that its supplementation during circulatory shock provides
protective reduction rather than toxic inhibition of cellular respiration. Finally, according to the currently available literature, neither inhalation of gaseous \( \text{H}_2\text{S} \) nor injection of the soluble sulfide salts, \( \text{NaSH} \) or \( \text{Na}_2\text{S} \), is likely to become part of clinical practice because of damage to the airway mucosa and possibly toxic peak sulfide concentrations, respectively, but slow \( \text{H}_2\text{S} \)-releasing molecules may enable these limitations to be overcome. Hence, there is “nothing rotten about hydrogen sulfide’s medical promise” \([50]\), and \( \text{H}_2\text{S} \) clearly remains a “hot molecule” \([51]\) in the field of research for a possible pharmacological induction of suspended animation-like hypometabolism.

**List of abbreviations used**

CLP: coelical ligation and puncture; CNS: central nervous system; CPB: cardiopulmonary bypass; CPR: cardiopulmonary resuscitation; NADH: nicotinamide adenine dinucleotide.

**Competing interests**

The authors declare that they have no competing interests.

**Declarations**

Publication was funded thanks to support by the Deutsche Forschungsgemeinschaft (KFO 200, DFG RA 396/9-2), the Land Baden-Württemberg (Innovationsfond Medizin), and the Bundesministerium der Verteidigung (Vertragsforschungsvorhaben M/SAK/8A004).

**Author details**

1. Dptement de Reanimation Medicale et de Medecine Hyperbare, Centre Hospitalier Universitaire, 49933 Angers, France. 2. Sektion Anesthesiologische Pathophysiologie und Verfahrensentwicklung, Klinik für Anästhesiologie, Universitätsklinikum, 69081 Ulm, Germany.

**Published:** 18 March 2014

**References**

1. Suspended animation. [http://en.wikipedia.org/wiki/Suspended_animation] Accessed Nov 2013
2. Singer M, De Santis V, Vitale D, Jeffcoate W: Endocrine, metabolic, and biochemical responses. \( \text{H}_2\text{S} \) in unsedated mice and rats. Shock 2011, 36:359–364.
3. Drabek T, Kochanek PM, Stezoski J, Wu X, Bayir H, Morhard RC, Stezoski RC, Tisherman SA: Inhaled hydrogen sulfide does not increase resuscitability in a porcine model of prolonged cardiac arrest. Shock 2010, 34:190–195.
4. Fries M: Hydrogen sulfide does not increase resuscitability in a porcine model of prolonged cardiac arrest. Shock 2010, 34:190–195.
5. Tisherman SA, Drabek T: Hydrogen sulfide: metabolic mediator or toxic gas? Pediatr Crit Care Med 2008, 9:129–130.
6. Fries M: Hydrogen sulfide does not increase resuscitability in a porcine model of prolonged cardiac arrest. Shock 2010, 34:190–195.
7. Tisherman SA, Drabek T: Hydrogen sulfide: metabolic mediator or toxic gas? Pediatr Crit Care Med 2008, 9:129–130.
8. Fries M: Hydrogen sulfide does not increase resuscitability in a porcine model of prolonged cardiac arrest. Shock 2010, 34:190–195.
Wagner F, Scheuerle A, Weber S, Stahl B, McCook O, Knöferl MW, Huber-Lang M, Asfar P, Calzia E, Senftleben U, Gebhard F, Georgieff M, Radermacher P, Hyva V. Inflammatory effects of hypothermia and inhaled H2S during resuscitated, hyperdynamic murine septic shock. Shock 2011; 35:396–402.

Wagner F, Scheuerle A, Weber S, Stahl B, McCook O, Knöferl MW, Huber-Lang M, Seitz DH, Thomas J, Asfar P, Szabó C, Möller P, Gebhard F, Georgieff M, Calzia E, Radermacher P, Wagner K. Cardiopulmonary, histologic, and inflammatory effects of intravenous Na2S after blunt chest trauma. J Trauma 2011; 71:1659–1667.

Esechie A, Enkhaa.ByteArray, Traber DL, Jonkam C, Lange M, Hamahata A, Djukom C, Whorton EB, Hawkins HK, Traber LD, Szabo C. Beneficial effect of a hydrogen sulphide donor (sodium sulphide) in an ovine model of burn-and-smoke-induced acute lung injury. Br J Pharmacol 2009; 158:1442–1453.

Minamishima S, Bougaki M, Sips PY, Yu JD, Minashima YA, Elrod JW, Lefter DJ, Bloch KD, Ichinose F. Hydrogen sulfide improves survival after cardiac arrest and cardiopulmonary resuscitation via a nitric oxide synthase 3-dependent mechanism in mice. Circulation 2009; 120:888–896.

Sodha NR, Clements RT, Feng J, Liu Y, Bianchi C, Horvath EM, Szabo C, Sellke FW. Effects of therapeutic sulfide on myocardial apoptosis in response to ischemia-reperfusion injury. Eur J Cardiothorac Surg 2008; 33:906–913.

Ospov RM, Robach MP, Feng J, Chan V, Clements RT, Deyo RJ, Szabo C, Sellke FW. Effect of hydrogen sulfide on myocardial protection in the setting of cardioplegia and cardiopulmonary bypass. Interact Cardiovasc Thorac Surg 2010; 10:506–512.

Hunter JP, Hosgood SA, Patel M, Rose R, Read K, Nicholson ML. Effects of hydrogen sulphide in an experimental model of renal ischaemia-reperfusion injury. Br J Surg 2012; 99:1665–1671.

Chen Z, Chen H, Rhee P, Koustaeva E, Ayuste EC, Nonaka K, Nadel A, Alam HB. Induction of profound hypothermia modulates the immune/inflammatory response in a swine model of lethal hemorrhage. Resuscitation 2005; 66:209–216.

Cooper CE, Brown GC. The physiological and pharmacological properties of hydrogen sulfide: chemical mechanism and physiological significance. J Bioenerg Biomembr 2008; 40:353–359.

Gröger M, Mataello J, McCook O, Wagner F, Wachter U, Bastian O, Gierer S, Reich V, Stahl B, Huber-Lang M, Szabó C, Radermacher P, Calzia E, Wagner K. Temperature and cell-type dependency of sulfide effects on mitochondrial respiration. Shock 2013; 38:367–374.

Leverve X, Batandier C, Fontaine E. Choosing the right substrate. Nat Rev Endocrinol 2012; 8:1244–1255.

Drabek T. Hydrogen sulfide – a hot molecule. Antioxid Redox Signal 2010; 12:1147–1154.

Roth MB, Nystul T. Buying time in suspended animation. Sci Am 2005; 292:48–55.

Leslie M. Nothing rotten about hydrogen sulfide’s medical promise. Science 2008; 320:1155–1157.

Aslami H, Schultz MJ, Juffermans NP. Hydrogen sulfide: a hot molecule. Anesthesiology 2011; 115:921–922.